144 related articles for article (PubMed ID: 21931655)
1. Bioluminescence-based high-throughput screen identifies pharmacological agents that target neurotransmitter signaling in small cell lung carcinoma.
Improgo MR; Johnson CW; Tapper AR; Gardner PD
PLoS One; 2011; 6(9):e24132. PubMed ID: 21931655
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
[TBL] [Abstract][Full Text] [Related]
3. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
[TBL] [Abstract][Full Text] [Related]
4. Bromodomain and hedgehog pathway targets in small cell lung cancer.
Kaur G; Reinhart RA; Monks A; Evans D; Morris J; Polley E; Teicher BA
Cancer Lett; 2016 Feb; 371(2):225-39. PubMed ID: 26683772
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
[TBL] [Abstract][Full Text] [Related]
6. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway.
Yang CL; Liu YY; Ma YG; Xue YX; Liu DG; Ren Y; Liu XB; Li Y; Li Z
PLoS One; 2012; 7(5):e37960. PubMed ID: 22662257
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
[TBL] [Abstract][Full Text] [Related]
8. Identification of inhibitors of ABCG2 by a bioluminescence imaging-based high-throughput assay.
Zhang Y; Byun Y; Ren YR; Liu JO; Laterra J; Pomper MG
Cancer Res; 2009 Jul; 69(14):5867-75. PubMed ID: 19567678
[TBL] [Abstract][Full Text] [Related]
9. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
10. TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495.
Ye M; Wei T; Wang Q; Sun Y; Tang R; Guo L; Zhu W
Biochem Biophys Res Commun; 2017 Apr; 486(2):349-356. PubMed ID: 28302484
[TBL] [Abstract][Full Text] [Related]
11. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
Li H; Wang H; Deng K; Han W; Hong B; Lin W
Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
[TBL] [Abstract][Full Text] [Related]
12. Fibroblast growth factor-inducible 14 regulates cell growth and multidrug resistance of small-cell lung cancer through the nuclear factor-κB pathway.
Li X; Zhu W; Chen Z; Luo L; Huang J; Zhang F; Li M; Guo Y; Guo L
Anticancer Drugs; 2014 Nov; 25(10):1152-64. PubMed ID: 25054270
[TBL] [Abstract][Full Text] [Related]
13. [DDP-sensitivity-related genes in 10 lung cancer cell lines].
Li CH; Cai L; Chen XS; Meng QW; Sui GJ
Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):418-21. PubMed ID: 19024514
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin and photodynamic therapy exert synergistic inhibitory effects on small-cell lung cancer cell viability and xenograft tumor growth.
Cheng YS; Peng YB; Yao M; Teng JP; Ni D; Zhu ZJ; Zhuang BF; Yang ZY
Biochem Biophys Res Commun; 2017 Jun; 487(3):567-572. PubMed ID: 28431928
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of role of Notch3 signaling pathway in human lung cancer cells.
Hassan WA; Yoshida R; Kudoh S; Motooka Y; Ito T
J Cancer Res Clin Oncol; 2016 May; 142(5):981-93. PubMed ID: 26838758
[TBL] [Abstract][Full Text] [Related]
16. Harnessing the lysosome-dependent antitumor activity of phenothiazines in human small cell lung cancer.
Zong D; Zielinska-Chomej K; Juntti T; Mörk B; Lewensohn R; Hååg P; Viktorsson K
Cell Death Dis; 2014 Mar; 5(3):e1111. PubMed ID: 24625970
[TBL] [Abstract][Full Text] [Related]
17. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
[TBL] [Abstract][Full Text] [Related]
18. Study of small-cell lung cancer cell-based sensor and its applications in chemotherapy effects rapid evaluation for anticancer drugs.
Guohua H; Hongyang L; Zhiming J; Danhua Z; Haifang W
Biosens Bioelectron; 2017 Nov; 97():184-195. PubMed ID: 28599178
[TBL] [Abstract][Full Text] [Related]
19. A high-throughput drug screen identifies auranofin as a potential sensitizer of cisplatin in small cell lung cancer.
Liu X; Wang W; Yin Y; Li M; Li H; Xiang H; Xu A; Mei X; Hong B; Lin W
Invest New Drugs; 2019 Dec; 37(6):1166-1176. PubMed ID: 30825105
[TBL] [Abstract][Full Text] [Related]
20. Discovery of degradable niclosamide derivatives able to specially inhibit small cell lung cancer (SCLC).
He X; Li M; Ye W; Zhou W
Bioorg Chem; 2021 Feb; 107():104574. PubMed ID: 33383327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
